BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

71 related articles for article (PubMed ID: 11086960)

  • 1. Comments on the Cox model of cyclophosphamide hematotoxicity.
    Krishnan K
    J Toxicol Environ Health A; 2000 Nov; 61(5-6):511-4. PubMed ID: 11086960
    [No Abstract]   [Full Text] [Related]  

  • 2. From cyclophosphamide hematotoxicity to modeling cancer.
    Luebeck EG
    J Toxicol Environ Health A; 2000 Nov; 61(5-6):515-20. PubMed ID: 11086961
    [No Abstract]   [Full Text] [Related]  

  • 3. Biologically based risk assessment model for cyclophosphamide hematotoxicity in animal species: concluding comments.
    Andersen ME; Krewski D
    J Toxicol Environ Health A; 2000 Nov; 61(5-6):543-52. PubMed ID: 11086966
    [No Abstract]   [Full Text] [Related]  

  • 4. A biomathematical model of cyclophosphamide hematotoxicity.
    Cox LA
    J Toxicol Environ Health A; 2000 Nov; 61(5-6):501-10. PubMed ID: 11086959
    [No Abstract]   [Full Text] [Related]  

  • 5. Comments on a biochemical model of cyclophosphamide hematotoxicity.
    Portier CJ; Parham FM
    J Toxicol Environ Health A; 2000 Nov; 61(5-6):525-8. PubMed ID: 11086963
    [No Abstract]   [Full Text] [Related]  

  • 6. A clinician's comments on the cyclophosphamide hematotoxicity biologically based risk assessment model.
    Atkins HL
    J Toxicol Environ Health A; 2000 Nov; 61(5-6):529-38. PubMed ID: 11086964
    [No Abstract]   [Full Text] [Related]  

  • 7. Introduction of the hematotoxicity modeling workshop.
    Krewski D; Henry C
    J Toxicol Environ Health A; 2000 Nov; 61(5-6):499-500. PubMed ID: 11086958
    [No Abstract]   [Full Text] [Related]  

  • 8. Review of the Cox model.
    Chen C
    J Toxicol Environ Health A; 2000 Nov; 61(5-6):521-3. PubMed ID: 11086962
    [No Abstract]   [Full Text] [Related]  

  • 9. Review of the Cox hematotoxicity model.
    Heaney ML; Nimer SD
    J Toxicol Environ Health A; 2000 Nov; 61(5-6):539-41. PubMed ID: 11086965
    [No Abstract]   [Full Text] [Related]  

  • 10. Comparison of CFU-GM response to piperazinedione versus cyclophosphamide in normal mice.
    OKunewick JP; Buffo MJ; Kociban DL
    Exp Hematol; 1984 Jun; 12(5):297-300. PubMed ID: 6547096
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Validation and development of a predictive paradigm for hemotoxicology using a multifunctional bioluminescence colony-forming proliferation assay.
    Rich IN; Hall KM
    Toxicol Sci; 2005 Oct; 87(2):427-41. PubMed ID: 16002476
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Hematopoietic stem cells.
    Quesenberry P; Levitt L
    N Engl J Med; 1979 Oct; 301(14):755-61. PubMed ID: 384246
    [No Abstract]   [Full Text] [Related]  

  • 13. Effect of H2 antagonists cimetidine and famotidine on the hemotoxicity of cyclophosphamide.
    Lerza RA; Bogliolo GV; Mencoboni MP; Saviane AG; Pannacciulli IM
    Anticancer Res; 1988; 8(6):1241-5. PubMed ID: 2905881
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evaluation of the protection of murine bone marrow stem cells by WR-2721 during in vitro treatment with mafosfamide.
    Jiang R; Bony V; Lopez M
    Prog Clin Biol Res; 1994; 389():23-9. PubMed ID: 7700906
    [No Abstract]   [Full Text] [Related]  

  • 15. [The toxic action of antineoplastic chemotherapeutic agents evaluated by study of hemopoietic stem cells].
    Pannacciulli I; Ghio R; Bianchi G; Bogliolo G; Saviane A; Massa G
    Minerva Med; 1978 Dec; 69(61):4257-65. PubMed ID: 366466
    [No Abstract]   [Full Text] [Related]  

  • 16. Single high doses of cyclophosphamide enable the collection of high numbers of hemopoietic stem cells from the peripheral blood.
    Gianni AM; Siena S; Bregni M
    Exp Hematol; 1991 Feb; 19(2):147-8. PubMed ID: 1991496
    [No Abstract]   [Full Text] [Related]  

  • 17. Stem-cell survival and tumor control in the Lewis lung carcinoma.
    Steel GG; Adams K
    Cancer Res; 1975 Jun; 35(6):1530-5. PubMed ID: 1169108
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Effects of erythropoietic activation on the hemotoxicity of cyclophosphamide].
    Bogliolo G; Ronco D; Massa G; Dolcino G; Mansi C; Pannacciulli I
    Arch Maragliano Patol Clin; 1973; 29(2):153-7. PubMed ID: 4808341
    [No Abstract]   [Full Text] [Related]  

  • 19. Nonhuman primates in evaluation of hematotoxicity.
    Saslaw S; Carlisle HN
    Ann N Y Acad Sci; 1969 Jul; 162(1):646-58. PubMed ID: 4979575
    [No Abstract]   [Full Text] [Related]  

  • 20. Bone cancer risk of (239)pu in humans derived from animal models.
    Bijwaard H; Dekkers F
    Radiat Res; 2007 Nov; 168(5):582-92. PubMed ID: 17973546
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.